Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Active Chronic Graft Versus Host Disease Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

NCT02112071
View directory record Official record
Conditions
Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 14, 2026, 5:29 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity

NCT04427709
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Knee
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD

NCT02099799
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis
Interventions
Pedometer and Website
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 14, 2026, 5:29 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

O2 Transport and Utilization in Health and Lung Disease

NCT04014712
View directory record Official record
Conditions
COPD, Tetrahydrobiopterin Deficiency, Oxidative Stress
Interventions
Tetrahydrobiopterin, Placebo oral tablet
Drug
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

NCT01221298
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

NCT02006732
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT02487498
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anaheim, California • Escondido, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Behavioral Rx & Nutrition in Pediatric Chronic Disease

NCT01018121
View directory record Official record
Conditions
Pediatric Obesity
Interventions
LAUNCH, Pediatrician Counseling
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 5 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

NCT01964352
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo, olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

NCT02884206
View directory record Official record
Conditions
Chronic Heart Failure (CHF)
Interventions
LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 14, 2026, 5:29 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)

NCT01349608
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Physical Activity, Health Behavior
Interventions
Telephonic health coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Pilot Trial for Adults With Acquired Brain Injury

NCT05793827
View directory record Official record
Conditions
Acquired Brain Injury, Traumatic Brain Injury, Stroke
Interventions
Adapted Hatha Yoga, Low-Impact Exercise
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hockey Fans in Training (Hockey FIT): Improving Men's Health Through the Power of Sport

NCT03636282
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Hockey FIT Program (Immediate Delivery)
Behavioral
Lead sponsor
Western University, Canada
Other
Eligibility
35 Years to 65 Years · Male only
Enrollment
997 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Flint, Michigan • Saginaw, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

NCT00118768
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, Pegylated Interferon Alfa
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Timeline
Started 2005
U.S. locations
19
States / cities
Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 14, 2026, 5:29 AM EDT
Terminated Phase 3 Interventional Results available

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Clazakizumab, Physiologic saline solution
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 14, 2026, 5:29 AM EDT
Not listed No phase listed Observational

The Epigenetics of Exercise and Physical Activity in COPD

NCT03539042
View directory record Official record
Conditions
Copd
Interventions
Not listed
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

NCT02525523
View directory record Official record
Conditions
Pouchitis
Interventions
Alicaforsen, Placebo
Drug
Lead sponsor
Atlantic Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 14, 2026, 5:29 AM EDT
Recruiting Not applicable Interventional

Physical Capacity Building for Chronic Stroke

NCT07039305
View directory record Official record
Conditions
Stroke, Post-stroke Depression
Interventions
Physical capacity training for chronic stroke - building aerobic capacity and muscle strength
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 14, 2026, 5:29 AM EDT
Completed Early Phase 1 Interventional

Adapted High-Intensity Virtual Reality Exergaming

NCT07155213
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Virtual reality exergaming
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
13 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 5:29 AM EDT